Drug profile · INN
obecabtagene autoleucel
AUCATZYL
obecabtagene autoleucel (AUCATZYL) is a b-lymphocyte antigen cd19 binding agent. Associated with Autolus GmbH.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XL
Patents linked 6
Pipeline programs 6
News articles 0
Drug details — obecabtagene autoleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 6
- Programs
- 6
- Data quality
- 0.89
Quick answer
obecabtagene autoleucel (AUCATZYL) is a b-lymphocyte antigen cd19 binding agent. Associated with Autolus GmbH.
Key facts
INN obecabtagene autoleucel
Brand AUCATZYL
Mechanism B-lymphocyte antigen CD19 binding agent
Target B-lymphocyte antigen CD19
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XL
Originator Autolus GmbH
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is obecabtagene autoleucel?
obecabtagene autoleucel (AUCATZYL) is a b-lymphocyte antigen cd19 binding agent. Associated with Autolus GmbH.
What is the brand name for obecabtagene autoleucel?
AUCATZYL is a marketed brand name for obecabtagene autoleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.